Barrigel, a NASHA spacer, helps to reduce radiation delivered to the rectum during prostate cancer radiation therapy. Credit: MattL_Images / Shutterstock.com.

Medical technologies provider Teleflex has signed a definitive agreement to take over Palette Life Sciences for an upfront cash deal of $600m.

Palette will also receive an additional $50m from Teleflex based on certain commercial milestone achievements.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

With the addition of non-animal stabilised hyaluronic acid (NASHA) spacer and tissue bulking products, the acquisition will broaden the Teleflex Interventional Urology portfolio, encompassing the UroLift System.

The new additions via the acquisition will help enhance patient outcomes in urology and urogynecology disorders, colorectal conditions and radiation oncology procedures.

Palette offers Barrigel, a NASHA spacer intended to reduce radiation delivered to the rectum during prostate cancer radiation therapy while enhancing tumour control.

Designed to be easily shaped, Barrigel is clearly visible on transrectal ultrasound and can be assembled in one step at any location. It is also biodegradable and reversible.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Palette’s portfolio also features Deflux and Solesta, the two NASHA-based tissue bulking agents specifically developed to address paediatric vesicoureteral reflux and faecal incontinence, respectively.

Teleflex chairman, president and CEO Liam Kelly said: “The acquisition of Palette Life Sciences will allow us to incorporate this exciting technology into our interventional urology business unit and bring urologists, radiation oncologists and other specialists more innovative technologies that can positively impact patient care.

“The transaction is consistent with our strategy to acquire assets that are accretive to Teleflex’s growth rate.”

Subject to customary closing conditions, the deal is expected to be completed in the fourth quarter of this year.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact